Announcement
Announcement Under Reg 30 Of SEBI (LODR) 6 Aug - SEBI appointed CNK & Associates LLP for forensic audit covering FY2020-21 to FY2025-26.
Source: Bse
Nath Bio-Genes (India) Limited (NATHBIOGEN)
Small CapPharma stocks · Small cap · NSE
Nath Bio-Genes (India) Limited operates in Seeds, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals18 Oct 2026 · screener
Latest result29 Jul, 09:46 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
54Neutralfull bear SMA stack · SMA20 -7.2% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 24
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
NATHBIOGEND candles · FIT view-19.7%Latest close ₹135.71 on 2026-10-19
Bar
-1.7%
RSI
37
MACD hist
0.19
52W pos
12%
2026-10-19O ₹138.00H ₹138.22L ₹134.06C ₹135.71Vol 7,868 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NATHBIOGENNifty PharmaNifty 500
- NATHBIOGEN
- -17.0%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -11.5 pp
Chart stats
19 Oct 2026- From 52W high
- -33.5%
- 52W range position
- 12%
- ATR (14)
- 4.1%
- Volume vs 20D
- 0.31x
- Avg traded value
- ₹0.3 Cr
- 20D price channel
- ₹133 - ₹154.9
₹204
₹126.2 - ₹204
₹5.6
Latest completed session
20-session average
31.7% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST35
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent75
Revenue +15.5% · PAT +14.3% YoY
Technical
Neutral54
Price trend and sector-relative-strength timing.
Valuation
Legacy model-123.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence55
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 75/100Rev +15% YoY · PAT +14% YoY · margin expansion · +531% QoQ
Filed 29 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹328 Cr | +15.5% | +530.8% |
| EBITDA | ₹35 Cr | +20.7% | +775.0% |
| Operating margin | 11.0% | +100 bps | +200 bps |
| PAT | ₹32 Cr | +14.3% | NDF |
| PAT margin | 9.8% | -10 bps | +976 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 7.73
- P/B
- 0.39
- EV/EBITDA
- 7.55
- Market Cap
- 262.00Cr
Profitability
- ROE
- 5.33%
- ROCE
- 7.16%
- ROA
- 3.56%
- Dividend Y
- 1.49%
Growth (CAGR)
- Revenue 5Y
- -15.00%
- EPS 5Y
- -15.00%
- Revenue 3Y
- 15.00%
- EPS 3Y
- -0.81%
Balance Sheet
- Debt/Equity
- 0.20
- Interest Coverage
- 2.88×
- Altman Z
- 2.04
- Book Value
- 358.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- -13.00 Cr
- EPS TTM
- 20.35
Shareholding
- Promoter Hold
- 45.59%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 15%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 328+530.8% vs prev
Net Profit
₹ CrLatest: 32.0
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 37. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~7.7% over last month) — short-term momentum negative.
- RSI(14) at 37 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 33% off 52W high · 8% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
31
RS percentile
Stage 1 Base / Transition
1M return
-7.9%
3M return
-17.0%
6M return
-20.8%
1Y return
-19.8%
RS 1D
0
RS 20D
-12
Sector rank
#1
Industry rank
#65
Stage evidence
- Price is 14.4% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed -0.3% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
improving
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 84.07-0.40%
RS vs Nifty 50084
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · WATCHLISTValuation24/30
Growth1/25
Quality0/20
Balance Sheet9/15
Cash Flow2/10
Piotroski
4/9 (+1)
Penalties
-2
Raw sum
35
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
35/100 · legacy band WATCHLIST
Positive drivers
- Valuation contributes 24/30 to the score.
- Balance sheet contributes 9/15 to the score.
- Cash flow contributes 2/10 to the score.
Main drags
- Penalty bucket subtracts 2 points.
- Fair-value margin of safety is negative at -123.8%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
7.7
PB
0.4
EV/EBITDA
7.5
ROE
5.3%
ROCE
7.2%
FCF Yield
—
Debt/Equity
0.2
MoS
-123.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
35
Previous: 35
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-123.8%
Previous: -123.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
35
35
35
35
35
35
35
35
35
35
35
35
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹404.87
+66.5% MoS
Growth-justified P/E
3.0
Growth-justified Value
₹60.64
-123.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INDOUS
Small
Indo Us Biotech Limited
Biotechnology
match 135
42
29.9
16.9%
+43%
WATCHLIST
AJOONI
Small
Ajooni Biotech Limited
Biotechnology
match 130
56
13.5
4.3%
+72%
FAIR VALUE
SHEEL
SME
Sheel Biotech Ltd.
Biotechnology
match 127
60
10.4
11.2%
+76%
UNDERVALUED
HESTERBIO
Small
Hester Biosciences Limited
Biotechnology
match 120
57
33.7
15.9%
+28%
FAIR VALUE
BIOCON
Mid
Biocon Limited
Biotechnology
match 116
32
78.9
1.4%
-2833%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Nath Bio-Genes (India) Limited operates in Seeds, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
55Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 16th percentile of the scored universe and 11th percentile within Pharma. Main check: cash conversion is weak at 40/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
99 docs text-extracted · 36 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
16th percentile
overall median 67 · Pharma: 11th pctile, median 70 · Small: 18th pctile, median 66
Evidence depth
Financial-only
99 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
40
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
40
weak · capital discipline
Results
43
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸3/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-13 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 7.1%.
- ▸ROE is low at 5.5%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Nath Bio-Genes (India) Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationJul 2026
Jul 2026 · PPT
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.